2 April 2019 - Many new medicines have been listed on the PBS in the first four months of 2019. Can the current high rate of new listings last?

Below is a summary of the new medicines that have been (or will be listed) on the PBS/LSDP so far this calendar year.

January 2019

• Tolvaptan (Jinarc)

February 2019

• Guselkumab (Tremfya)
• Osimertinib mesylate (Tagrisso)
• Tildrakizumab (Ilumya)

March 2019

• Bictegravir sodium with emtricitabine and tenofovir alafenamide fumarate (Biktarvy)
• Venetoclax (Venclexta)

April 2019

• Cerliponase alfa (Brineura) - LSDP
• Safinamide mesylate (Xadago)
• Sofosbuvir with velpatasvir and voxilaprevir (Vosevi)

May 2019 

• Avelumab (Bavencio)
• Palbociclib (Ibrance)

This analysis does not include new indications.

Insofar as a Federal election looming, the current rate of new PBS listings is unlikely to continue in the short to medium term. A list of the new medicines recommended by the PBAC in recent times but yet to be listed on the PBS will be published in tomorrow's issue of MAESTrO Daily.